School of Life Sciences, University of Science and Technology of China, Hefei, China.
State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, The Chinese Academy of Sciences, Beijing, China.
J Med Genet. 2019 Jan;56(1):10-17. doi: 10.1136/jmedgenet-2018-105405. Epub 2018 Jul 20.
Chimeric antigen receptor T (CAR-T) cells engineered with lentiviral and retroviral vectors have been successfully applied to treat patients with B cell malignancy. However, viral integration in T cells has the potential risk of mutagenesis, and viral vector production demands effort and is costly. Using non-integrative episomal vector such as minicircle vector to generate integration-free CAR-T cells is an attractive option.
We established a novel method to generate minicircle vector within a few hours using simple molecular biology techniques. Since no bacteria is involved, we named these vectors bacteria-free (BF) minicircle. In comparison with plasmids, BF minicircle vector enabled higher transgene expression and improved cell viability in human cell line, stem cells and primary T cells. Using BF minicircle vector, we generated integration-free CAR-T cells, which eliminated cancer cells efficiently both in vitro and in vivo.
BF minicircle vector will be useful in basic research as well as in clinical applications such as CAR-T and gene therapy. Although the transgene expression of minicircle vector lasts apparently shorter than that of insertional lentivirus, multiple rounds of BF minicircle CAR-T cell infusion could eliminate cancer cells efficiently. On the other hand, a relatively shorter CAR-T cell persistence provides an opportunity to avoid serious side effects such as cytokine storm or on-target off-tumour toxicity.
使用慢病毒和逆转录病毒载体工程改造的嵌合抗原受体 T(CAR-T)细胞已成功应用于治疗 B 细胞恶性肿瘤患者。然而,T 细胞中的病毒整合具有潜在的突变风险,并且病毒载体的生产需要付出努力并且成本高昂。使用非整合性的附加体载体(如微环载体)来产生无整合的 CAR-T 细胞是一个有吸引力的选择。
我们建立了一种使用简单分子生物学技术在数小时内生成微环载体的新方法。由于不涉及细菌,我们将这些载体命名为无细菌(BF)微环。与质粒相比,BF 微环载体在人细胞系、干细胞和原代 T 细胞中实现了更高的转基因表达和改善的细胞活力。使用 BF 微环载体,我们生成了无整合的 CAR-T 细胞,这些细胞在体外和体内都有效地消除了癌细胞。
BF 微环载体将在基础研究以及 CAR-T 和基因治疗等临床应用中有用。尽管微环载体的转基因表达持续时间明显短于插入性慢病毒,但多次 BF 微环 CAR-T 细胞输注可以有效地消除癌细胞。另一方面,CAR-T 细胞的相对较短的持续时间为避免细胞因子风暴或靶标外肿瘤毒性等严重副作用提供了机会。